mRNA |
selumetinib:GDC-0941 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0004 |
mRNA |
YM-155 |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
0.0006 |
mRNA |
niclosamide |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.001 |
mRNA |
selumetinib:piperlongumine (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.002 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.002 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.002 |
mRNA |
selumetinib:tretinoin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.002 |
mRNA |
Crizotinib |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.003 |
mRNA |
BRD-K03911514 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
0.004 |
mRNA |
Sorafenib |
GDSC1000 |
pan-cancer |
AAC |
0.16 |
0.004 |